Bone substitute enters orthopaedic trial:
This article was originally published in Clinica
ETEX, a biomaterials company based in Cambridge, Massachusetts, has begun a US clinical trial of its Alpha-BSM bone substitute material in non-diaphyseal tibia fractures. The product is already cleared in the US for dental, periodontal and craniofacial applications but approval for orthopaedic applications could open it up to a potential $465 million market. The trial will likely be completed by the beginning of next year, said ETEX.
You may also be interested in...
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.